ORAQUICK HCV RAPID ANTIBODY TEST

Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus

FDA Premarket Approval P080027 S001

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for the oraquick hcv rapid antibody test is a single-use immunoassay for the qualitative detection of antibodies to hepatitis c virus (anti-hcv) in fingerstick whole blood specimens and venipuncture whole blood specimens (edta, sodium heparin, lithium heparin, and sodium citrate) from individuals 15 years or older. The oraquick hcv rapid antibody test results, in conjunction with other laboratory results and clinical information, may be used to provide presumptive evidence of infection with hcv (state of infection or associated disease not determined) in persons with signs or symptoms of hepatitis and in persons at risk for hepatitis c infection.

DeviceORAQUICK HCV RAPID ANTIBODY TEST
Classification NameAssay, Enzyme Linked Immunosorbent, Hepatitis C Virus
Generic NameAssay, Enzyme Linked Immunosorbent, Hepatitis C Virus
ApplicantORASURE TECHNOLOGIES INC.
Date Received2010-08-03
Decision Date2011-02-18
Notice Date2011-03-09
PMAP080027
SupplementS001
Product CodeMZO
Docket Number11M-0132
Advisory CommitteeMicrobiology
Supplement TypePanel Track
Supplement ReasonLabeling Change - Indications/instructions/shelf Life/tradename
Expedited ReviewNo
Combination Product No
Applicant Address ORASURE TECHNOLOGIES INC. 220 East First Street bethlehem, PA 18015
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P080027Original Filing
S039 2021-03-25 30-day Notice
S038 2021-02-01 30-day Notice
S037 2020-09-14 30-day Notice
S036
S035 2019-08-16 30-day Notice
S034 2018-11-07 30-day Notice
S033 2018-03-13 30-day Notice
S032 2018-01-08 30-day Notice
S031 2017-12-08 30-day Notice
S030 2017-09-14 30-day Notice
S029 2017-08-14 30-day Notice
S028 2017-06-07 30-day Notice
S027 2017-04-14 30-day Notice
S026 2017-01-30 30-day Notice
S025 2016-11-28 30-day Notice
S024 2016-10-24 30-day Notice
S023 2016-04-15 30-day Notice
S022 2016-02-01 30-day Notice
S021 2015-09-03 30-day Notice
S020
S019 2014-12-23 30-day Notice
S018 2014-09-03 Special (immediate Track)
S017 2014-06-06 Real-time Process
S016 2014-03-04 Normal 180 Day Track
S015 2013-11-19 30-day Notice
S014 2013-09-06 30-day Notice
S013 2013-08-28 30-day Notice
S012 2013-07-12 Special (immediate Track)
S011 2013-04-29 Special (immediate Track)
S010 2013-02-21 30-day Notice
S009 2013-02-19 Special (immediate Track)
S008 2012-12-28 30-day Notice
S007 2012-11-28 Special (immediate Track)
S006 2011-04-06 30-day Notice
S005 2011-03-16 135 Review Track For 30-day Notice
S004
S003 2011-02-23 135 Review Track For 30-day Notice
S002
S001 2010-08-03 Panel Track

NIH GUDID Devices

Device IDPMASupp
00608337000542 P080027 001
20608337000539 P080027 001

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.